[1]严天海,任冬弓,李先穆,等.非肌层浸润膀胱癌组织中ROC1，UBC9水平表达与临床病理学特征及肿瘤电切术预后的相关性研究[J].现代检验医学杂志,2025,40(03):64-68,74.[doi:10.3969/j.issn.1671-7414.2025.03.012]
　YAN Tianhai,REN Donggong,LI Xianmu,et al.Expression of ROC1, UBC9 in Non-muscle Invasive Bladder Cancer Tissues and Their Correlation with Clinicopathological Characteristics and Prognosis of Tumor Resection[J].Journal of Modern Laboratory Medicine,2025,40(03):64-68,74.[doi:10.3969/j.issn.1671-7414.2025.03.012]
点击复制

非肌层浸润膀胱癌组织中ROC1，UBC9水平表达与临床病理学特征及肿瘤电切术预后的相关性研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年03期
页码:
64-68,74
栏目:
论著
出版日期:
2025-05-15

文章信息/Info

Title:
Expression of ROC1, UBC9 in Non-muscle Invasive Bladder Cancer Tissues and Their Correlation with Clinicopathological Characteristics and Prognosis of Tumor Resection
文章编号:
1671-7414（2025）03-064-06
作者:
严天海，任冬弓，李先穆，姚宏涛，吴勤智，郝 燚
（西北大学第一医院泌尿外科，西安 710043）
Author(s):
YAN Tianhai，REN Donggong，LI Xianmu，YAO Hongtao，WU Qinzhi，HAO Yi
(Department of Urology， Northwest University First Hospital, Xi’an 710043，China)
关键词:
非肌层浸润膀胱癌; Cullins调节因子1; 泛素结合酶9; 经尿道膀胱肿瘤电切术
分类号:
R737.14；R730.43
DOI:
10.3969/j.issn.1671-7414.2025.03.012
文献标志码:
A
摘要:
目的研究非肌层浸润膀胱癌（NMIBC）中Cullins调节因子1（ROC1）、泛素结合酶9（UBC9）表达与临床病理特征及经尿道膀胱肿瘤电切术（TURBT）预后的评估价值。方法回顾性分析2018年4月～2021年2月西北大学第一医院行TURBT的104例NMIBC患者。采用免疫组织化学(IHC)检测组织ROC1，UBC9表达。随访三年，采用Kaplan-Meier曲线分析和COX回归分析影响NMIBC患者预后的因素。结果NMIBC癌组织中ROC1（67.31%），UBC9（69.23%）阳性率高于癌旁组织（9.62%，7.69%），差异具有统计学意义（χ2=73.125，83.200，均P＜0.001）。NMIBC中ROC1与UBC9表达呈正相关（r=0.719，P＜0.001）。肿瘤最大径≥2cm，T1期癌组织中ROC1（87.23%，90.00%），UBC9（89.36%，88.33%）阳性率高于肿瘤最大径＜2cm（50.88%，52.63%），Ta/Tis期（36.36%，43.18%）患者癌组织，差异具有统计学意义（χ2=15.474～33.188，均P＜0.05）。TURBT术后出现膀胱肿瘤局部复发29例，转移10例，死亡2例，三年无进展生存率（PFS）为60.58%（63/104）。ROC1阳性组和阴性组NMIBC患者三年PFS为47.14%（33/70），88.24%（30/34）；UBC9阳性组和阴性组患者三年PFS为47.22%（34/72），90.63%（29/32），差异具有统计学意义（Log-rankχ2=15.341，15.931，均P＜0.001）。多因素COX回归分析，ROC1阳性、UBC9阳性、肿瘤最大径≥2cm，T1期是影响NMIBC患者预后的危险因素（Waldχ2=6.408～11.010，均P＜0.001）。结论NMIBC中ROC1，UBC9表达升高，与肿瘤最大径及肿瘤分期有关，联合检测ROC1，UBC9有助于评估NMIBC患者的预后。
Abstract:
Objective To study the expression of regulator of cullins-1(ROC1) and ubiquitin binding enzyme 9 (UBC9) in non-muscle invasive bladder cancer(NMIBC) and their relationship with clinicopathological features and prognostic value of transurethral resection of bladder tumor (TURBT). Methods Retrospective analysis was conducted on 104 patients with NMIBC who underwent TURBT at Northwest University First Hospital from April 2018 to February 2021. Immunohistochemistry was used to detect the expression of ROC1 and UBC9 in tissues. Follow-up was conducted for 3 years, and Kaplan-Meier curve analysis and COX regression analysis were used to identify factors affecting the prognosis of NMIBC patients. Results The positive rates of ROC1 (67.31%) and UBC9 (69.23%) in NMIBC cancer tissues were higher than those in adjacent tissues（9.62%， 7.69%）, and the differences were statistically significant (χ2=73.125, 83.200, all P<0.001). There was a positive correlation between the expression of ROC1 and UBC9 in NMIBC cancer (r=0.719, P<0.001). The positivity rates of ROC1(87.23%， 90.00%) and UBC9(89.36%，88.33%) in cancer tissues with a maximum tumor diameter of ≥ 2cm, T1 stage were higher than those in cancer tissues with a maximum tumor diameter of<2cm（50.88%，52.63%）, Ta/Tis stage（36.36%，43.18%）, and the difference were statistically significant (χ2=15.474 ～ 33.188, all P<0.05). After TURBT surgery, there were 29 cases of local recurrence, 10 cases of metastasis, and 2 deaths of bladder cancer, the 3-year progression-free survival (PFS) rate was 60.58% (63/104). The 3-year PFS of NMIBC patients in the ROC1 positive and negative groups was 47.14% (33/70) and 88.24% (30/34),and the 3-year PFS of patients in the UBC9 positive and negative groups was 47.22% (34/72) and 90.63% (29/32),the differences were statistically significant(Log-rank χ2=15.341, 15.931, all P<0.001). Multivariate COX regression analysis showed that ROC1 positivity，UBC9 positivity，maximum tumor diameter ≥ 2cm and T1 phase were risk factors affecting the prognosis of NMIBC patients (all P<0.001).Conclusion The expression of ROC1 and UBC9 is elevated in NMIBC, which is related to the maximum diameter and stage of the tumor. Combined detection of ROC1 and UBC9 can help evaluate the prognosis of NMIBC patients.

参考文献/References:

[1] LOBO N,AFFERI L,MOSCHINI M, et al. Epidemiology, screening, and prevention of bladder cancer [J]. European Urology Oncology, 2022, 5(6): 628-639.
[2] 杜君,段鹏强,张超,等.术前全身炎症反应指数对中高危非肌层浸润性膀胱癌预后的影响[J].中国肿瘤临床,2023,50(16):829-833. DU Jun, DUAN Pengqiang, ZHANG Chao, et al. Impact of preoperative systemic inflammatory response index on the prognosis of intermediate-to-high-risk non-muscle invasive bladder cancer [J]. Chinese Journal of Clinical Oncology, 2023, 50(16): 829-833.
[3] WANG Yu, TAN Mingjia, LI Hua, et al. Inactivation of SAG or ROC1 E3 ligase inhibits growth and survival of renal cell carcinoma cells: effect of BIM[J]. Translational Oncology, 2019, 12(6): 810-818.
[4] MARIAN I M, VONK P J, VALDES I D, et al. The transcription factor roc1 is a key regulator of cellulose degradation in the wood-decaying mushroom Schizophyllum commune [J]. mBio, 2022, 13(3): 6282-6292.
[5] SHEN Nirui, WANG Qingting, QIU Yuanjie, et al. Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis[J]. Medicine (Baltimore), 2022, 101(26): e29806.
[6] BIALIK P, WYSOKINSKI D, SLOMKA M, et al. HRM screening of the UBC9 gene encoding the SUMO-E2-conjugating enzyme - case-control study in breast cancer [J]. Experimental Oncology , 2020, 42(2): 130-134.
[7] SABATINI M E, COMPAGNONI M, MAFFINI F, et al. The UBC9/SUMO pathway affects E-cadherin cleavage in HPV-positive head and neck cancer [J]. Frontiers in Molecular Biosciences, 2022, 9: 940449.
[8] 季新灿,郭浩阳,汪伟,等.1990-2019年中国膀胱癌发病率趋势[J].济宁医学院学报,2023,46(2):90-95. JI Xincan, GUO Haoyang, WANG Wei, et al. Incidence trend of bladder cancer in China from 1990 to 2019:an age-period-cohort analysis [J]. Journal of Jining Medical University, 2023, 46(2): 90-95.
[9] PISZCZEK R, KRAJEWSKI W, SUBIELA J D, et al. Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus calmette-guérin immunotherapy [J]. Minerva Urology and Nephrology, 2023, 75(5): 591-599.
[10] 朱军,沈欣,曹冬.非肌层浸润性膀胱癌组织中PKM2和ALYREF表达及与预后预测价值研究[J].现代检验医学杂志,2023,38(5):110-114. ZHU Jun, SHEN Xin, CAO Dong. Expression of PKM2 and ALYREF in non-muscular invasive bladder cancer and their prognostic value [J]. Journal of Modern Laboratory Medicine, 2023, 38(5): 110-114.
[11] WU Qi, ZHOU Xiaoqing, LI Peng, et al. ROC1 promotes the malignant progression of bladder cancer by regulating p-IκBα/NF-κB signaling[J]. Journal of Experimental& Clinical Cancer Research, 2021, 40(1): 158.
[12] ZHANG X H, XIN Z M. MiR-135b-5p inhibits the progression of malignant melanoma cells by targeting RBX1[J]. European Review for Medical and Pharmacological Sciences, 2020, 24(3): 1309-1315.
[13] WANG W, QIU J, QU P, et al. Regulator of cullins-1(ROC1) negatively regulates the Gli2 regulator SUFU to activate the hedgehog pathway in bladder cancer[J]. Cancer Cell International, 2021, 21(1): 75.
[14] LIU Xijuan, ZURLO G, ZHANG Qing. The roles of cullin-2 E3 ubiquitin ligase complex in cancer [J]. Advances in Experimental Medicine and Biology, 2020, 12(7): 173-186.
[15] AL-SHARAKY D R, KANDIL M A E H, AIAD H A S, et al. ROC-1, P21 and CAIX as markers of tumor aggressiveness in bladder carcinoma in Egyptian patients[J]. Diagnostic Pathology, 2020, 15(1): 33.
[16] FUKUYAMA T, KITAMURA T, KOZU T. UBC9 inhibits myeloid differentiation in collaboration with AML1-MTG8[J]. International Journal of Hematology, 2022, 115(5): 686-693.
[17] GHOSH D K, PANDE S, KUMAR J, et al. The E262K mutation in lamin A links nuclear proteostasis imbalance to laminopathy-associated premature aging[J]. Aging Cell, 2022, 21(11): e13688.
[18] HUANG Xiaoliang, TAO Yuting, GAO Jiamin, et al. UBC9 coordinates inflammation affecting development of bladder cancer[J]. Scientific Reports, 2020, 10(1): 20670.
[19] CHEN Zhengxin, WANG Shuai, LI Hailin, et al. FOSL1 promotes proneural-to-mesenchymal transition of glioblastoma stem cells via UBC9/CYLD/NF-κB axis[J]. Molecular Therapy, 2022, 30(7): 2568-2583.
[20] CHEN Changchen, ZHENG Hanhao, LUO Yuming, et al. SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer[J]. the Journal of Clinical Investigation, 2021, 131(8): 1464-1472.
[21] BIEDERST?DT A, HASSAN Z, SCHNEEWEIS C, et al. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype[J]. Gut, 2020, 69(8): 1472-1482.
?

相似文献/References:

[1]朱军,沈欣,曹冬.非肌层浸润性膀胱癌组织中PKM2 和ALYREF 表达及与预后预测价值研究[J].现代检验医学杂志,2023,38(05):110.[doi:10.3969/j.issn.1671-7414.2023.05.021]
　ZHU Jun,SHEN Xin,CAO Dong.Expression of PKM2 and ALYREF in Non-muscular Invasive Bladder Cancer and Their Prognostic Value[J].Journal of Modern Laboratory Medicine,2023,38(03):110.[doi:10.3969/j.issn.1671-7414.2023.05.021]
[2]吴 楠,孙立如,李亚东,等.非肌层浸润性膀胱癌组织中OTUD5 和RNF186 表达与临床病理特征的关系及预后价值研究[J].现代检验医学杂志,2024,39(05):75.[doi:10.3969/j.issn.1671-7414.2024.05.014]
　WU Nan,SUN Liru,LI Yadong,et al.Study on the Clinicopathological Characteristics and Prognostic Value of the Expression of OTUD5 and RNF186 in Non-muscle Invasive Bladder Cancer[J].Journal of Modern Laboratory Medicine,2024,39(03):75.[doi:10.3969/j.issn.1671-7414.2024.05.014]

备注/Memo

备注/Memo:
基金项目：陕西省科学技术厅科技计划项目（2021JQ-719）。
作者简介：严天海（1981-），男，本科，主治医师，研究方向：泌尿系统肿瘤，E-mail：yanth123456@163.com。
通讯作者：任冬弓，E-mail：196079449@qq.com。
更新日期/Last Update: 2025-05-15